Global Hyoscine-N-Butyl Bromide market will reach 460.31 million US$ by the end of 2026

Publisher: QYResearch
Published Date: 2019/10/24

Hyoscine-N-Butyl Bromideis obtained from a species of the plant genus Duboisia. It is mainly classified as an antispasmodic, which means that it is a drug used to suppress of muscle spasms, or involuntary contractions.

The production of Hyoscine-N-Butyl Bromideis increased from 59.93 MT in 2014 to 85.92 MT in 2018, at a CARG 9.43%. The manufacturers are Boehringer-Ingelheim, Linnea, Alchem International and Alkaloids.

Boehringer-Ingelheim is the world leader with 81.74% of market share in 2018. Boehringer-Ingelheim produces both Hyoscine-N-Butyl Bromideis API and Buscopan. They mainly sale Buscopan in market and the revenue of Buscopan is 236 EUR million in 2016.

According to region, Europe is the largest production region with 88.78% of production share in 2018 followed by India, holding about 11.04% of market share. Also there are some Buscopan manufacturers in India. There are few producers in China in recent years and the Buscopan manufacturers are mainly imported the raw materials from India or Europe.

According to end application, Hyoscine-N-Butyl Bromideis are mainly used to synthesis Hyoscine-N-Butyl Bromideis oral Hoscine-N-Butyl Bromideis solution. In 2018, Hyoscine-N-Butyl Bromideis oral holds mostly of Hyoscine-N-Butyl Bromideis, holding about 67.62% sales share.

Click to view the full report:
https://www.qyresearch.com/index/detail/712697/global-hyoscine-n-butyl-bromide-industry
This article was first released by QYResearch, if reproduced, please indicate the source.
Telephone number:020-86655165
Contact:press@qyresearch.com
When contacting, please refer to QYR company's Mia introduction.